SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
NanoViricides Inc. (NNVC) on Tuesday reported a loss of $2.2 million in its fiscal second quarter. On a per-share basis, the ...
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...
SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NNVC) (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that ...
NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antivirals, said on Tuesday it has filed an application with the US Food and Drug Administration (FDA) for ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results